Main Topic: The development of a pancreatic cancer vaccine using mRNA technology, which has shown promising results in a small clinical trial.
Key Points:
Participants:
Takeaways:
Implications:
Sean Rameswaram
For the longest time, cancer vaccines were a pipe dream. It was too risky a strategy for such a powerful immune weapon. And so we had to, for the entire history of cancer, we had surgery, chemotherapy, and radiation therapy. Basically treating it like a monster, trying to destroy Godzilla without destroying Tokyo in the process.
Charles Graber
That's right. And in the last few years, there's been a sea change in the thinking around treating cancer. And that's really opened up the field of immunotherapy and the possibility of treating cancer like any other disease, including through vaccines.
Sean Rameswaram
And that's what we're seeing here in this study. Scientists at Memorial Sloan Kettering in New York City just released the results of a clinical trial on a pancreatic cancer vaccine. And the results could be a game changer.
Vinod Balachandran
I'm a surgeon at Memorial Sloan Kettering Cancer Center. I take care of patients with pancreatic cancer, and I also run a laboratory here where we're trying to find new ways to use the immune system to fight pancreatic cancer.
Sean Rameswaram
So, Dr. Balachandran, why pancreatic cancer?
Vinod Balachandran
Pancreatic cancer is a deadly cancer, soon to become the second leading cause of cancer death in the United States by 2025. And part of the reason for this is because the current treatments that we use for pancreatic cancer, which include surgery, chemotherapy, and radiation, are largely ineffective.
Charles Graber
And despite these best treatments, survival rates for pancreatic cancer patients remain only around 12%. So really pointing to an urgent need for new treatments for pancreatic cancer.
Vinod Balachandran
The simple question that we started with was 88 percent or so of pancreatic cancer patients die despite their best current treatments, but a rare 12 percent or so do not, and they receive essentially the same treatments as other patients, but they have really exceptional long-term survival.
Charles Graber
So in these long-term survivors, we think their immune systems are able to recognize their own cancers in a very strong way that we think helps them survive this long.
Vinod Balachandran
So the question then led to what is the immune system actually seeing? And by understanding what the immune system was seeing, could we now teach other patients' immune systems to recognize their own cancers in a similar way that these long-term survivors recognize their cancers?
Sean Rameswaram
And that's what this study is about. A clinical trial on a pancreatic cancer vaccine. Can you walk us through how it works?
Vinod Balachandran
So, we started the idea for this clinical trial in 2017 with a company that was not as well known at the time called BioNTech that is based out of Germany.
Charles Graber
And BioNTech is run by two scientists who happen to be married to one another. But it was sort of this small little known German company that was known to be working in cancer drugs using messenger RNA to try to fight cancer in this really cutting way.
Vinod Balachandran
We vaccinated 16 patients in this clinical trial. This is a small phase one clinical trial. The primary endpoint of this clinical trial was safety, meaning we designed the number of patients that we would test in to make sure the vaccines are safe.
Sean Rameswaram
So, how did it go? I mean, how did this vaccine work for the 16 people who got it?
Vinod Balachandran
What we found is when we give these vaccines to pancreatic cancer patients, we see that these vaccines are, number one, they're safe. Number two, they're feasible, meaning you can make fast vaccines individualized for cancer patients in real time.
Charles Graber
But interestingly, what we also found in these patients is that the vaccines were able to teach patients immune systems to recognize their own cancers in 8 of 16 patients. So 50% of the patients, the vaccines were able to teach their own immune systems to recognize their own cancers using mRNA vaccines.
Vinod Balachandran
So half of the patients didn't have a response. What was supposed to happen is a T-cell army geared specifically to identify, target, and kill cancer cells, those specific cancer cells. It didn't arise. But in the other half, it did happen.
Charles Graber
You had a T-cell army, a clone army built up. In fact, in some cases, when they measured the T cells, they found that as many as 10% of the T cells in circulation in the bloodstream at that point were oriented towards finding cancer if it showed up again, if a tumor regrew.
Vinod Balachandran
And they found that in that group that did respond, that did have the T cell army build up and trained on those wanted posters they'd injected and created in the body, there was no relapse of pancreatic cancer. And in the other half, there was within 13 months.
Sean Rameswaram
So, Dr. Balachandran, what does this mean for the future of cancer treatment?
Vinod Balachandran
It's really exciting. Cool. I'm excited. This is exciting. I love it. It's contagious. I mean, not in like a diseasy way. Hopefully not.
Charles Graber
It is really exciting. I mean, this is the fruit of the breakthrough that happened only a few years ago, and in a way that very few people understood it. It's the basis of the Biden moonshot. It's the thing that cured Jimmy Carter's brain cancer. You know, he had it, and you thought, oh, he's old, and he's got brain cancer. Well, that's you know, that's that, and then he didn't, and those were all immunotherapies.
Vinod Balachandran
And it's all based on an understanding counter to everything that everyone in medical school was taught until very recently that cancer can be seen by the immune system can be killed by the immune system, and you just have to learn to take the brakes off the immune system, the brakes that the cancer applies to the immune system.
Charles Graber
And then you can successfully target. We were never going to cure cancer with the war on cancer as it was. Cut, poison, and burn didn't include the immune system. And you were never going to cure a mutating, tricky disease like cancer with things that don't mutate, basically.
Vinod Balachandran
And now the scientists I speak to talk about this as a penicillin moment in our war against cancer. It's that big of a deal.
Sean Rameswaram
Charles, can you explain why this is such a big deal?
Charles Graber
The idea of cancer vaccines is not a new one because it's a disease. And, you know, we've had vaccines for over 100 years. So the idea that you could possibly make a vaccine against cancer, why not? But the immune system and cancer didn't seem to interact the way the immune system works with other diseases.
Vinod Balachandran
And for that reason, it was believed that, yeah, you can't use the immune system. You can't weaponize or help the immune system to fight cancer. It's just it doesn't work that way.
Charles Graber
Despite that, some people kept on trying to make vaccines. The most basic version of a vaccine is, you know, you basically take the disease, chop it up, put it in a blender. And so it just is a series of parts or you kill it or make it really weak, and you reintroduce it into somebody's system, you inject it into them.
Vinod Balachandran
So the immune system gets a sneak peek at what the enemy might look like if it ever shows up. And it can train on those weak diseases or the dead pieces of the diseases to learn to identify them.
Charles Graber
That works with a lot of disease, but a couple problems with it. One, it can be dangerous to inject a disease into someone that doesn't have it, even if it's a weakened disease. And two, we didn't take into account some of the countermeasures that diseases have to foil the immune system.
Vinod Balachandran
The mRNA stuff is really the game changer here. If COVID had an upside, besides improving our ability to do jigsaw puzzles and binge watch... Sourdough bread. Sourdough bread has really benefited from the pandemic for sure.
Charles Graber
The technology that leapt forward in order to meet that challenge as quickly as possible, this mRNA technology, everything came together at the right time, our ability to sequence genomes, to quickly read what the blueprints of cells were, and to make that into another blueprint that we can re-inject.
Vinod Balachandran
That was really the basis of the COVID vaccine. And the difference there is that, you know, the COVID virus has these unique spikes, hence the corona thing. Those spikes, you know, instead of giving the immune system the whole virus, you just give them the spikes.
Charles Graber
You just basically send in the working blueprints to code for those spikes, say, hey, body, make a whole bunch of these spikes. Train your immune system on recognizing those spikes. You see anything with those spikes, nail it.
Vinod Balachandran
And then you've got this whole army ready for that. And then it shows up and they're there in numbers and all trained up. So we just did the same thing here with cancer.
Charles Graber
So what's new here isn't the idea of a cancer vaccine. What new here is that we have mRNA technology that we can apply to a cancer vaccine. That part of it. What new is that we understand the immune system and cancer better and differently than we ever have before.
Vinod Balachandran
So the idea of a vaccine isn't new. This approach is new. And there are also some other new drugs that we have that we can use alongside this stuff, things that block cancer's secret handshake, help prevent the cancer from applying the brakes to the immune system or trying to trick it into not attacking.
Charles Graber
We can dampen those and help go around them. We just basically didn't understand the disease. We thought we did, but we really didn't. And we definitely didn't understand the immune system, which is, it's like the deep ocean of biology. It's incredibly complex and weird.
Sean Rameswaram
Charles, do you think if these types of vaccines, cancer vaccines, these bespoke sort of customized, individualized cancer vaccines that use mRNA technology can be produced at scale one day in the near distant future, that they could sort of transcend the amount of skepticism people had towards mRNA technology and the COVID vaccines?
Charles Graber
I think there are always going to be flat earthers that essentially are opposed to sending genetic directions back into your body, full stop. And, you know, armed with a little bit of science and a basic misunderstanding, I think there's always going to be skeptics and hand wavers.
Vinod Balachandran
However, when it comes to cancer, it feels like people can dismiss COVID as the flu, whereas cancer is not regarded that way, and it really isn't that way.
Charles Graber
So I feel it'll be treated differently. But your question about scaling is really interesting, and you can see a future where it's really easy to genotype your tumor and your normal body cell because you just stick it into a machine that does that, and really easy to then use an AI program to figure out the best neoantigens, the best targets within the differences between your normal cells and your mutated cells to target, and then code that back into something, a fatty thing, and just crank it out in your local pharmacy in one machine.
Vinod Balachandran
You go in, you get your biopsy tumors sent in along with your normal body cells, and you end up with this stuff that you can get at your Walgreens or something, or if they figure out, okay, everybody's different and everyone's going to need a different one, but not really everyone's going to need a different one.
Charles Graber
You only need maybe 500,000 different variations and we've got them all ready to go. So your number 35789B, okay, that's the one we're going to get and it's ready to go. You just program that in.
Vinod Balachandran
You can imagine that's what's going to happen in the future. Scalability seems inevitable to me. It's bespoke now because it's new, you know, and it'll always be customized, but it'll be sort of like, you know, if you can order a suit by just taking pictures of your body and sending it in and have it be a customized suit and you have to go to Savile Row or Hong Kong or something.
Sean Rameswaram
Charles, how will this eventually compare the idea of treating cancer with vaccines to the existing cancer treatments we have, chemo and the rest?
Charles Graber
Immunotherapy, taking the brakes off the immune system when it comes to identifying and killing cancer, combined with killing the cancer in conventional physical means, that actually turns out to be a really effective combination.
Vinod Balachandran
So what we'll probably see in the future is more of what we're seeing now, which are combinations of approaches, not one totally supplanting the other, but a series of strikes in different directions that complement each other.
Charles Graber
The experts I do speak to have been really firm in their belief that cancer should be looked at as a curable or chronic disease in the future, which is to say one that you manage but isn't a death sentence.
Vinod Balachandran
I wouldn't want to speculate, but I think that what cancer looks like in 10 years is going to be markedly different. And in 20 years, I would expect all that science fiction, George Jetson projection stuff that we were talking about with making vaccines by just plugging in numbers and ordering them up to be commonplace.
Sean Rameswaram
Charles, can I ask you, can I start smoking cigarettes again because I'll eventually have a treatment for it?
Charles Graber
Oh, totally. Bring it on, right? I need the cigarettes to deal with all the other maladies and that I need the vaccine to deal with the cigarettes.
Vinod Balachandran
Yeah, no, it's really hopeful and really exciting. I mean, the reason I wrote the breakthrough, the truth is it really is the most exciting medical development in our lifetime. And most people don't understand it or realize that we're there, that something fundamental has changed.
Sean Rameswaram
Charles, thank you for helping us understand it today. I really appreciate it.
Charles Graber
Thanks for being as excited about it as I am. This is really cool stuff.
Sean Rameswaram
Thanks also to Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center in New York City. Avishay Artsy produced today's show with help from Matthew Collette, Laura Bullard, and Michael Raphael. I'm Sean Rameswaram from Today Explained. Don't smoke cigarettes, kids. You'll smell like an ashtray. Thank you.